Dual inhibition of the RAS-RAF-MEK-ERK and EGFR-downstream PI3K-AKT-mTOR pathways using BRAF, MEK, ERK, and EGFR inhibitors has been suggested to be effective for treating KRAS/BRAF–mutant CRC cells [9]. This evidence concerns the gene MTOR and colorectal carcinoma.